|
Dapagliflozin tablets are indicated for the treatment of heart failure in adults.
The receipt of this permission paves way for the launch of Dapagliflozin Tablets in India for the specified indication, subject to the receipt of related statutory approvals and licenses, said the drug maker.
Astrazeneca Pharma India is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company.
The company's standalone net profit declined 38.3% to Rs 17.27 crore in Q4 FY23 as compared with Rs 27.98 crore in Q4 FY22. Net sales jumped 22.7% year on year to Rs 284.70 crore in Q4 FY23.
The scrip hit a 52-week high at Rs 3,882.70 in intraday today on the BSE.
|